GLAND

GLAND PHARMA

Large Cap BSE: 543245 NSE: GLAND
₹1726.65
11.05 (0.64%)
As on 10 December, 2022 | 13:31

Gland Pharma Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Start SIP in GLAND PHARMA

Start SIP

Gland Pharma Share Price

Gland Pharma Share Returns

  • Over 1 Month -2.54%
  • Over 3 Month -27.78%
  • Over 6 Month -38.34%
  • Over 1 Year -51.75%

Gland Pharma Key Statistics

P/E Ratio 27.6
PEG Ratio -3.5
Market Cap Cr 28,436
Price to Book Ratio 4
EPS 73.4
Dividend 0
Relative Strength Index 42.73
Money Flow Index 51.44
MACD Signal -58.04
Average True Range 56.69

Gland Pharma Investment Rating

  • Master Rating:
  • Gland Pharma has an operating revenue of Rs. 4,067.64 Cr. on a trailing 12-month basis. An annual revenue growth of 29% is outstanding, Pre-tax margin of 37% is great, ROE of 16% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 73 which is a FAIR score but needs to improve its earnings, a RS Rating of 1 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at E which indicates heavy supply, Group Rank of 112 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Gland Pharma Financials
IndicatorSep 2022Jun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021
Oper Rev Qtr Cr 1,0488571,1031,0631,0801,154888
Operating Expenses Qtr Cr 753587755714704718560
Operating Profit Qtr Cr 295270348349377436328
Depreciation Qtr Cr 37353128262525
Interest Qtr Cr 2121111
Tax Qtr Cr 837995939912189
Net Profit Qtr Cr 240229286273302351260

Gland Pharma Technicals

EMA & SMA

Current Price
1726.65
11.05 (0.64%)
  • Bullish Moving Average
  • ___
  • 0
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • 1759.49
  • 50 Day
  • 1894.85
  • 100 Day
  • 2116.27
  • 200 Day
  • 2438.09
  • 20 Day
  • 1734.63
  • 50 Day
  • 1902.23
  • 100 Day
  • 2118.16
  • 200 Day
  • 2566.2

Gland Pharma Resistance and Support

PIVOT
₹1719.25
Resistance
First Resistance 1735.3
Second Resistance 1755
Third Resistance 1771.05
RSI 42.73
MFI 51.44
MACD Single Line -58.04
MACD -46.71
Support
First Resistance 1699.55
Second Resistance 1683.5
Third Resistance 1663.8

Gland Pharma Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 201,020 10,698,284 53.22
Week 308,057 14,497,181 47.06
1 Month 509,552 21,365,494 41.93
6 Month 483,832 27,283,274 56.39

Gland Pharma Result Highlights

Gland Pharma Synopsis

NSE-Medical-Generic Drugs

Gland Pharma is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 4400.71 Cr. and Equity Capital is Rs. 16.43 Cr. for the Year ended 31/03/2022. Gland Pharma Ltd. is a Public Limited Listed company incorporated on 20/03/1978 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24239TG1978PLC002276 and registration number is 002276.
Market Cap 28,436
Sales 4,072
Shares in Float 6.92
No of funds 190
Yield
Book Value 3.96
U/D Vol ratio 0.6
LTDebt / Equity
Alpha -0.28
Beta 0.49

Gland Pharma

Owner NameSep-22Jun-22Mar-22Dec-21
Promoters 57.86%57.87%58%
Mutual Funds 18.48%15.54%11.22%
Insurance Companies 2.1%1.17%0.72%
Foreign Portfolio Investors 6.1%9.41%10.72%
Financial Institutions/ Banks
Individual Investors 3.78%3.71%3.69%
Others 11.68%12.3%15.65%

Gland Pharma Management

Name Designation
Mr. Yiu Kwan Stanley Lau Chairman & Ind.Director
Mr. Srinivas Sadu Managing Director & CEO
Mr. Qiyu Chen Non Executive Director
Mr. Yifang Wu Non Executive Director
Mr. Yao Fang Non Executive Director
Ms. Xiaohui Guan Non Executive Director
Mr. Udo Johannes Vetter Independent Director
Dr. Jia Ai (Allen) Zhang Non Executive Director
Mr. Satyanarayana Murthy Chavali Independent Director
Mr. Essaji Goolam Vahanvati Independent Director
Ms. Naina Lal Kidwai Independent Director

Gland Pharma Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Gland Pharma Corporate Action

Date Purpose Remarks
2022-10-26 Quarterly Results
2022-07-20 Quarterly Results
2022-05-19 Audited Results
2022-01-21 Quarterly Results
2021-10-22 Quarterly Results

Gland Pharma MF Shareholding

Name Amount(cr)
ICICI Prudential Balanced Advantage Fund Growth 44618
Axis Bluechip Fund Growth 36891
ICICI Prudential Bluechip Fund Growth 35929
Mirae Asset Large Cap Fund Regular Growth 35407
Axis Long Term Equity Fund Growth 31583

About Company

Gland Pharma is the leading company in creating some of the most beneficial injectable products that have significance in multiple therapeutic segments. In addition, the company is responsible for creating an online portfolio that allows users to buy their products online with a doctor's prescription. Right now, the company is manufacturing its products in seven different locations in India and which produce 750 million units with ease. The four major manufacturing facilities of the company have 22 production lines in order to provide finished formulations along with the Active Pharmaceutical Ingredient (API) Facilities as well. All the products that the company manufactures are delivered in the form of liquid vials, syringes that are pre-filled, ampoules, drops, and even bags as well. 

In addition to this, the company is also putting a lot of effort into research for manufacturing and creating a delivery system that could hold complex injectables like peptides, suspensions, and long-lasting injectables. Apart from this, Gland Pharma Ltd is also putting its efforts into research and development of synthesizing some of the most complex molecules for the production of their injectables. Lastly, Gland Pharma Ltd is building the market of niche products in the pharmaceutical industry in India and throughout the world. 
 

Products offered by Gland Pharma Ltd.

  • Anti Malarials
  • Anti-Infectives
  • Anti-Neoplastics
  • Blood Related
  • Cardiac
  • Gastro Intestinal
  • Gynaecological
  • Hormones
  • Neuro / Cns
  • Ophthal / Otologicals
  • Others
  • Pain / Analgesics
  • Respiratory
  • Vitamins / Minerals / Nutrients

 

Gland Pharma Ltd is listed on 2 exchanges, and these are:

 

  • National Stock Exchange of India Ltd.
  • The Stock Exchange, Mumbai


Included in Indices

 

  • NIFTY 50 - No 
  • NIFTY next 50 - YES
  • NIFTY 100 - YES
  • S&P BSE 200 - YES
  • S&P BSE 250 large midcap index- YES
  • S&P BSE finance- NO

 

Other listing information

 

  • Incorporation date - March 20 1978
  • BSE group - A 
  • BSE Code - 543245
  • NSE - GLANDEQ

 

History

 

1978
PVN Raju establishes Gland Pharma to manufacture and market Heparin injection in the domestic market, as well as to provide contract manufacturing services to other pharmaceutical companies.


1994
From a private limited company, it becomes a public limited company.


1996
Becomes the first company to establish a PFS facility in India.

2000
Signs its first Contract Manufacturing agreement for regulated markets

2007
Enters the US market with Ketorolac PFS


2013
Entered European markets with Tirofiban
The Visakhapatnam Oncology Formulations Facility has been approved by the USFDA.


2016
In 2016, the USFDA granted the first approval for a Penems plant in Hyderabad, as well as a Sterile Injectable plant in Pashamylaram, Hyderabad.
First USFDA approval for an API plant in VSEZ and another in Pharmacity, Visakhapatnam.


2017
Fosun Pharma acquired a majority stake in the company.


2018
Enoxaparin injection received US market approval in 2018.
The first ophthalmic product has been approved for sale in the United States.

Gland Pharma FAQs

What is Share Price of Gland Pharma ?

Gland Pharma share price is ₹1726 As on 10 December, 2022 | 13:17

What is the Market Cap of Gland Pharma ?

The Market Cap of Gland Pharma is ₹28436.2 Cr As on 10 December, 2022 | 13:17

What is the P/E ratio of Gland Pharma ?

The P/E ratio of Gland Pharma is 27.6 As on 10 December, 2022 | 13:17

What is the PB ratio of Gland Pharma ?

The PB ratio of Gland Pharma is 4 As on 10 December, 2022 | 13:17

Is it a good time to invest in Gland Pharma Limited?

Gland Pharma has an operating revenue of Rs.3,981.54 Cr. on a trailing 12-month basis. An annual revenue growth of 30% is outstanding, Pre-tax margin of 39% is great. Various broking houses and analysts recommend 'BUY' on the stock.

What is the stock price CAGR of Gland Pharma Limited?

The stock price CAGR of Gland Pharma Limited for 1 Year is 66%.

Is Gland Pharma Limited debt-free?

Gland Pharma Limited is debt-free and has a strong balance sheet enabling it to report stable earnings growth across business cycles.

What is the ROE of Gland Pharma Limited?

The ROE of Gland Pharma Limited is 16% is which good.

Who is the Managing Director of Gland Pharma Limited?

Mr. Srinivas Sadu is the Managing Director & Chief Executive Officer of Gland Pharma Limited.

How to buy shares of Gland Pharma Ltd online?

The company's shares can be bought online or offline by opening a Demat account with 5Paisa and verifying the KYC documents.

What are some of the competitors of Gland Pharma Ltd?

Given below is the list of companies that belong to the same industry or manufacture products of a similar niche as Gland Pharma Ltd. 

  • Cipla 
  • Sun Pharma 
  • Pfizer 
  • Lupin
  • Eris Life 
  • Aarti Drugs 
  • Hester Bio
  • RPG Life 
  • Bafna Pharma 
  • Jb Chemicals 

Q2FY23